Onconetix, Inc. Files 8-K with Material Agreements and Officer Changes

Ticker: ONCO · Form: 8-K · Filed: 2025-07-16T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, management-change, corporate-action

Related Tickers: ONCO

TL;DR

Onconetix (ONCO) filed an 8-K detailing new deals and exec changes. Watch closely.

AI Summary

Onconetix, Inc. filed an 8-K on July 16, 2025, reporting on several key events. These include entering into a material definitive agreement, changes in directors and officers, and other significant events. The filing also covers financial statements and exhibits, with the company previously known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.

Why It Matters

This 8-K filing signals significant corporate activity at Onconetix, Inc., potentially impacting its strategic direction, leadership, and financial reporting.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.

Key Players & Entities

Onconetix, Inc. (company) — Registrant
Blue Water Biotech, Inc. (company) — Former company name
Blue Water Vaccines Inc. (company) — Former company name
July 16, 2025 (date) — Date of earliest event reported

FAQ

What is the nature of the material definitive agreement entered into by Onconetix, Inc.?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What specific changes occurred regarding directors or certain officers?

The filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as an item of information, but the specifics are not detailed in the provided text.

When did Onconetix, Inc. change its name from Blue Water Biotech, Inc.?

The date of the name change from Blue Water Biotech, Inc. to Onconetix, Inc. was April 24, 2023.

What is the SEC file number for Onconetix, Inc.?

The SEC file number for Onconetix, Inc. is 001-41294.

What is the primary business of Onconetix, Inc. according to its SIC code?

Onconetix, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

From the Filing

0001213900-25-064469.txt : 20250716 0001213900-25-064469.hdr.sgml : 20250716 20250716083717 ACCESSION NUMBER: 0001213900-25-064469 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20250716 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250716 DATE AS OF CHANGE: 20250716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 251126209 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0248815-8k_onconetix.htm CURRENT REPORT false 0001782107 0001782107 2025-07-16 2025-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 16, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 513 ) 620-4101     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01. Entry into a Material Definitive Agreement.   General Description of the Agreement and Plan of Merger   On July 16, 2025, Onconetix, Inc, a Delaware corporation (“ Onc